FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987272172> ?p ?o ?g. }

• W1987272172 endingPage "851" @default.
• W1987272172 startingPage "846" @default.
• W1987272172 abstract "In Brief BACKGROUND: Sugammadex is a modified γ cyclodextrin compound which encapsulates rocuronium resulting in rapid reversal of residual neuromuscular blockade. We performed a post hoc analysis of data from a multicenter study designed to mimic standard clinical practice which would test the hypothesis that the presence (versus the absence) of a twitch response to neuromuscular stimulation at the time of reversal drug administration would influence the speed and completeness of the reversal effect of sugammadex. METHODS: One-hundred-seventy-one consenting patients undergoing general anesthesia with a volatile-based anesthetic technique were enrolled in a multicenter observational study. All patients received rocuronium, 0.6 mg/kg IV for tracheal intubation and maintenance boluses of 0.15 mg/kg IV as needed during surgery. The degree of rocuronium-induced blockade was assessed during anesthesia using a TOF-Watch®-SX acceleromyograph to record the train-of-four (TOF) responses on a laptop computer from induction of anesthesia until the TOF ratio returned to ≥0.9 after completion of the surgical procedure. The patients received sugammadex, 4 mg/kg IV, for reversal of neuromuscular blockade >15 min after the last dose of rocuronium. Recovery data were compared in patients with either no (0) (n = 89) or ≥1 twitch (n = 82) in response to TOF stimulation at the time of reversal drug administration. RESULTS: The patients without a twitch response were more likely to be female (60% vs 40%) and had a shorter time interval between the last bolus dose of rocuronium and the administration of the reversal drug (31±18 vs 45±23 min, P < 0.05). The time to achieve a TOF ratio of 0.9 was prolonged in the 0 twitch group compared with the ≥1 twitch response group (173±162 vs 104±73 s, P < 0.05). Overall, 84% of the patients in the 0 twitch group recovered to a TOF of 0.9 in ≤5 min compared to 91% of the patients in the group with ≥1 twitch (P < 0.05). The times to achieve a TOF of 0.9 varied from 0.8 to 22.3 and 0.7 to 8.5 min in the 0 twitch and ≥1 twitch groups, respectively. CONCLUSION: Reversal of rocuronium-induced neuromuscular blockade by sugammadex was influenced by the degree of residual blockade at the time the reversal drug was administered. Despite the wide variability, reversal of the TOF ratio to 0.9 occurred ≤5 min in more than 80% of the patients regardless of the number of twitches at the time of reversal drug administration. IMPLICATIONS: Sugammadex, 4 mg/kg IV, given in the presence of ≥1 (vs 0) twitch responses in a train-of-four (TOF) was associated with a faster recovery to a TOF ratio of 0.9 (104±73 vs 173±162 s). Although residual rocuronium-induced neuromuscular blockade is rapidly reversed in most patients with sugammadex when it is administered >15 min after the last dose of the relaxant, 16% and 9% of the patients in the 0 and ≥1 twitch groups, respectively, failed to recover to a TOF of 0.9 within 5 min." @default.
• W1987272172 created "2016-06-24" @default.
• W1987272172 creator A5004205084 @default.
• W1987272172 creator A5008019866 @default.
• W1987272172 creator A5013878719 @default.
• W1987272172 creator A5018455544 @default.
• W1987272172 creator A5034429046 @default.
• W1987272172 creator A5043735195 @default.
• W1987272172 creator A5071163641 @default.
• W1987272172 date "2009-03-01" @default.
• W1987272172 modified "2023-09-24" @default.
• W1987272172 title "The Effect of Residual Neuromuscular Blockade on the Speed of Reversal with Sugammadex" @default.
• W1987272172 cites W1964741544 @default.
• W1987272172 cites W1968272727 @default.
• W1987272172 cites W1979448748 @default.
• W1987272172 cites W1993614648 @default.
• W1987272172 cites W1994129461 @default.
• W1987272172 cites W2059432091 @default.
• W1987272172 cites W2064517847 @default.
• W1987272172 cites W2071366551 @default.
• W1987272172 cites W2080204292 @default.
• W1987272172 cites W2112324095 @default.
• W1987272172 cites W2113544478 @default.
• W1987272172 cites W2113994462 @default.
• W1987272172 cites W2123379737 @default.
• W1987272172 cites W2149733694 @default.
• W1987272172 doi "https://doi.org/10.1213/ane.0b013e31818a9932" @default.
• W1987272172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19224792" @default.
• W1987272172 hasPublicationYear "2009" @default.
• W1987272172 type Work @default.
• W1987272172 sameAs 1987272172 @default.
• W1987272172 citedByCount "35" @default.
• W1987272172 countsByYear W19872721722012 @default.
• W1987272172 countsByYear W19872721722013 @default.
• W1987272172 countsByYear W19872721722014 @default.
• W1987272172 countsByYear W19872721722015 @default.
• W1987272172 countsByYear W19872721722016 @default.
• W1987272172 countsByYear W19872721722017 @default.
• W1987272172 countsByYear W19872721722018 @default.
• W1987272172 countsByYear W19872721722019 @default.
• W1987272172 countsByYear W19872721722020 @default.
• W1987272172 countsByYear W19872721722021 @default.
• W1987272172 countsByYear W19872721722023 @default.
• W1987272172 crossrefType "journal-article" @default.
• W1987272172 hasAuthorship W1987272172A5004205084 @default.
• W1987272172 hasAuthorship W1987272172A5008019866 @default.
• W1987272172 hasAuthorship W1987272172A5013878719 @default.
• W1987272172 hasAuthorship W1987272172A5018455544 @default.
• W1987272172 hasAuthorship W1987272172A5034429046 @default.
• W1987272172 hasAuthorship W1987272172A5043735195 @default.
• W1987272172 hasAuthorship W1987272172A5071163641 @default.
• W1987272172 hasBestOaLocation W19872721721 @default.
• W1987272172 hasConcept C126322002 @default.
• W1987272172 hasConcept C170493617 @default.
• W1987272172 hasConcept C206044474 @default.
• W1987272172 hasConcept C2776988050 @default.
• W1987272172 hasConcept C2778162923 @default.
• W1987272172 hasConcept C2778468042 @default.
• W1987272172 hasConcept C2778560516 @default.
• W1987272172 hasConcept C2778716859 @default.
• W1987272172 hasConcept C2909465803 @default.
• W1987272172 hasConcept C2911090098 @default.
• W1987272172 hasConcept C3020341438 @default.
• W1987272172 hasConcept C42219234 @default.
• W1987272172 hasConcept C71924100 @default.
• W1987272172 hasConceptScore W1987272172C126322002 @default.
• W1987272172 hasConceptScore W1987272172C170493617 @default.
• W1987272172 hasConceptScore W1987272172C206044474 @default.
• W1987272172 hasConceptScore W1987272172C2776988050 @default.
• W1987272172 hasConceptScore W1987272172C2778162923 @default.
• W1987272172 hasConceptScore W1987272172C2778468042 @default.
• W1987272172 hasConceptScore W1987272172C2778560516 @default.
• W1987272172 hasConceptScore W1987272172C2778716859 @default.
• W1987272172 hasConceptScore W1987272172C2909465803 @default.
• W1987272172 hasConceptScore W1987272172C2911090098 @default.
• W1987272172 hasConceptScore W1987272172C3020341438 @default.
• W1987272172 hasConceptScore W1987272172C42219234 @default.
• W1987272172 hasConceptScore W1987272172C71924100 @default.
• W1987272172 hasIssue "3" @default.
• W1987272172 hasLocation W19872721721 @default.
• W1987272172 hasLocation W19872721722 @default.
• W1987272172 hasLocation W19872721723 @default.
• W1987272172 hasOpenAccess W1987272172 @default.
• W1987272172 hasPrimaryLocation W19872721721 @default.
• W1987272172 hasRelatedWork W16745287 @default.
• W1987272172 hasRelatedWork W1977525022 @default.
• W1987272172 hasRelatedWork W1987272172 @default.
• W1987272172 hasRelatedWork W2102042659 @default.
• W1987272172 hasRelatedWork W2108798540 @default.
• W1987272172 hasRelatedWork W2306824249 @default.
• W1987272172 hasRelatedWork W2324128803 @default.
• W1987272172 hasRelatedWork W2965884268 @default.
• W1987272172 hasRelatedWork W3020171632 @default.
• W1987272172 hasRelatedWork W3134891845 @default.
• W1987272172 hasVolume "108" @default.
• W1987272172 isParatext "false" @default.
• W1987272172 isRetracted "false" @default.
• W1987272172 magId "1987272172" @default.

• next